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Reduction/Dissolution of the inorganic -MnOOH nanophase in the 
ferritin cavity to yield a high sensitiv, biologically compatible MRI agent** 
Ferenc Krisztián Kálmán, Simonetta Geninatti-Crich and Silvio Aime* 
The limited sensitivity of MRI is the major drawback to the 
thorough involvement of this modality in Molecular Imaging 
applications. Therefore the search for high sensitivity agents 
continues to be an active line of research in probe development 
laboratories[1]. Several nanocarriers have been considered in order to 
deliver a sufficient number of contrast agents to the targeting sites 
and to pursue their visualisation in MR images. For instance Lanza 
and Wickline reported solid-lipid microemulsions that can be loaded 
with 105 amphiphilic Gd-chelates and allow the detection of targets 
that are present at hundreds picomolar concentration[2]. Afterwards 
Mulder and Nicolay reported several successful examples of 
targeting probes using micelles and liposomes loaded with Gd-
complexes bearing lipidic chains[3]. Although, such particles display 
an excellent sensitivity, some concern exists for their use ”in vivo”, 
either for the metabolic fate of the amphiphilic Gd-complexes as 
well as for the macrophages uptake of the circulating particles. Both 
drawbacks are overcome if the particle consists of endogenous 
systems such as ferritin and the loaded agent has a well tolerated 
excrection profile. Some years ago we reported on the use of Gd-
loaded apoferritin[4-6] that displays a relaxivity of ca. 600-800 mM–
1s–1 per apoferritin. The system is extremely well tolerated, and it is 
not taken-up by macrophages. The attainable relaxation 
enhancement of Gd-loaded apoferritin is limited by the number of 
Gd-HPDO3A (Prohance) units (eight to ten) that is possible to 
entrap in the inner cavity of the protein with this procedure, based 
on H+-controlled deassembly/reassembly of the apoferritin vesicle. 
Thus, to tackle the task of a further marked relaxation enhancement 
of the apoferritin-based system, one needs to design a new approach 
of the loading procedure. 
Along the years, a number of studies have been devoted to 
understand the way through which iron ions enter the ferritin cavity 
and organize into ferri-oxy-hydroxy chains[7,8]. It has also been 
reported that other metal ions can be stored in high number inside 
the cavity[9,10]. Among them it has been shown that manganese ions 
enter the protein to yield nanosized crystals of -MnOOH[11]. Thus, 
a method is available to entrap a high number of paramagnetic ions 
inside the apoferritin cavity. However, to improve the T1-relaxation 
enhancement capabilities it is necessary to solubilize the metal ion 
payload in order to have MnII aqua ions able to transfer their 
paramagnetism to water molecules that freely exchange between the 
inner and outer compartment of the protein. Manganese is an 
essential metal and the biological systems have developed efficient 
routes to control its homeostasis. However, when administered as 
MnCl2 it displays a LD50 as low as 0.22 mmol/kg[1]. Thus the 
possibility of administering MnII ions sequestered in the apoferritin 
cavity should guarantee for a well tolerated system from which the 
Mn release would occur on a time scale compatible with its cellular 
homeostasis processes. 
The Mn-reconstituted apoferritin (Scheme 1) was prepared by 
incubating iron-free horse spleen apoferritin at pH = 9 in the 
presence of MnCl2 solution under air (see Supporting Information) 
by following a previously reported procedure[11]. 
 
 
Scheme 1.  Schematic representation of the Mn-Apo preparation. 
TEM images showed that Mn-ions form discrete mineral cores 
(MnOOH) within the ferritin shell (Figure 1). Experimental 
evidence for the formation of the Mn-core was also acquired by 
means of UV-Vis spectrophotometry as the increase of absorbance 
in the 400-500 nm range correlates with the formation of the 
MnOOH mineral[11]. Overall the incubation methodology at basic 
pH leads to a loading of ca. 3-4 thousands manganese per apoferritin. 
The MnIII to MnII reduction inside the inner cavity can be carried 
out by means of several reagent endowed with E0 < 1.5 V. It has not 
yet been definitely established how the core reduction takes place. 
Two mechanisms have been forwarded: 1) diffusion of the small 
reductant reagents through the three-fold channels and direct 
reaction at the mineral surface[12,13]or 2) electron transfer through 
the protein shell[15,16]. As reduction agents we have used two well 
known aminopolycarboxylic ligands, i.e. NTA and TETA whose 
oxydation typically occurs via N-dealkylation[17-19]. The treatment of 
Mn-reconstituted Apoferritin with NTA and TETA ligands allows to 
get the two tasks, i.e. elimination of any externally bound Mn ion 
and reduction of the internally loaded MnIII to MnII. The obtained 
product named Mn-Apo contains manganese only in its internal 
cavity whose speciation (MnII vs MnIII) is dependent upon the extent 
of the reductive treatment. 
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Figure 1. TEM image of Mn reconstituted apoferritin. 
By means of HPLC (Figure 2). it has been shown that most of 
Mn-Apo is under the monomeric form as established by the 




Figure 2. HPLC size exclusion chromatograms of native apoferritin 
compared with Mn-reconstituted apoferritin (without any reductive 
treatment) and with two samples of Mn-Apo treated for 4h with NTA 
and TETA, respectively. A volume of 200 l of 1 M protein solution 
was injected in the column using Hepes 5 mM and NaCl 0.14 M  (pH 
7.4) as aqueous mobile phase.  
The occurring complexation and redox reactions are represented 
by the following equations[17]: 
 
MnOOH  +  HxL(y-x)–    MnL(y-3)–  +  2OH–  +  (x-1)H+ 
 
Ly–  +  2MnOOH  +  5H+   
Lox(y-1)–  +  2Mn2+  +  CO2  +  HCHO  +  3H2O 
 
From the literature on ferritin[20-23], it is known that the release 
of FeII ions formed after a reductive treatment from the protein inner 
cavity is slow or impossible in the absence of specific chelators. The 
Mn-Apo system synthetised in this work behaves analogously. 
Figure 3a shows the NMRD profiles of the Mn-reconstituted 
apoferritin upon treatment with NTA or TETA. Both profiles 
display the characteristic dispersions of MnII aqua ion (at 0.02 and 
0.8 MHz). The NMRD profile of the MnII aqua ion is also shown for 
comparison (Figure 3b). The formation of MnII aqua ion upon the 
reduction of the MnOOH core was confirmed by acquiring the EPR 
spectrum that shows the characteristic six lines pattern (Figure 3c). 
As shown in Figure 3a the NMRD profiles change according to the 
duration of the treatment of the Mn-Apo samples with NTA and 
TETA ligands. The observed changes are indicative of differences in 
the manganese speciation that are the result of the incomplete 
reduction/elimination processes. The number of the MnII,III ions per 
apoferritin molecule also differs using NTA and TETA treatment, 
being 1090 ± 90 MnII,III ions after TETA treatment and 570 ± 60 
after NTA treatment, respectively. The different behavior shown by 
the two reagents reflects the complexity of the 
redox/complexation/elimination processes that undergo the 
formation of the Mn-Apo system. 
 
 
Figure 3. a) NMRD profiles, recorded at 25 °C, of Mn-reconstituted 
apoferritin (solid line); Mn-Apo obtained from the treatment with NTA 
(1:1 with respect to the total Mn concentration); reaction times: 5 (□), 
60 (◊)  and 180(⌂) minutes, respectively; Mn-Apo obtained from the 
treatment with TETA (1:1 with respect the total Mn concentration); 
reaction times: 5 (), 60 (●), 180 (▼), 240(◄), and 420(+) minutes. b) 
NMRD profiles, recorded at 25 °C, of a 1 mM solution of MnCl2. (The 
relaxivity values presented in Figure 3a and 3b are normalized to 1 
mM) c) EPR spectra recorded at RT of Mn-reconstituted apoferritin 
(bottom); Mn-Apo (obtained from the treatment with TETA, 1:1 with 
respect the total Mn concentration, 420’(middle) and of a MnCl2 
solution(top). (The MnII,III concentration of all EPR samples was 1 
mM.) 
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Taking into account the relaxivities of the samples treated with 
NTA and TETA and the relaxivities of the MnCl2, the amount of the 
free MnII aqua ions in the inner cavity of apoferritin can be 
determined. Free MnII has been estimated to be 20-25% in the case 
of NTA treatment and 30-40% in the case of TETA of the entrapped 
manganese in the protein shell, respectively. The other part of the 
metal is in MnOOH form. EPR data are in good agreement with 
these estimates (Figure 3c). 
The NMRD profiles of MnII complexes with NTA or TETA are 
characterized by a single dispersion at 5 MHz (Figure 4). The 
observed NMRD profiles of Mn-Apo does not show evidence for 
this feature although we can not exclude that some MnII complexes 
with NTA or TETA are present inside the inner cavity of apoferritin 
as their occurrence may be masked by the largely dominant 
contribution arising from MnII aqua ions. Alternatively, the absence 
of MnII complexes of NTA or TETA (or of their oxidation products) 
may be explained in terms of their facilitated release from the inner 
compartment of the protein. In the case of iron ions, it has been 
reported that small negatively charged complexes can be released 
whereas FeII aqua ions remain confined in the aqueous 
cavity[20,22,24,25]. Another explanation for the lack of MnII complexes 
may rely on the complete oxidation of the polyaminocarboxylate 
molecule that has entered the cavity thus yielding to products 
characterized by being not longer coordinating agents. 
 
 
Figure 4. NMRD profiles, recorded at 25°C, of Mn-NTA and Mn-TETA 
complexes. (The values are normalized to 1 mM concentration.) 
The stability of the Mn-Apo was assessed by measuring its 
NMRD profiles 1-2 weeks after the preparation. The results show 
that there was not release of MnII which is confirmed by the absence 
of the relaxivity hump at 30-35 MHz. Actually the prompt formation 
of MnII macromolecular adducts is observed upon the addition of a 
small aliquot of MnII ions containing solution. Thus, it has been 
found that Mn-Apo may reach a very high relaxivity due to the 
presence of about 1090 Mn atoms in the cavity with an average 
relaxivity of 6.2 ± 0.3 mM-1 s-1 at 20 MHz, 25 °C per Mn and in the 
range of ca. 4000-7000 mM-1s-1 per apoferritin molecule. 
 The Mn-Apo system shows markedly superior properties as 
MRI contrast agent as it displays a relaxivity (per apoferritin 
particle) that is almost one order of magnitude higher than that 
shown by Gd-loaded apoferritin. This achievement has been 
obtained thanks to the accumulation of a large number of manganese 
ions in its inner cavity.  
Finally, the recently raised concern on the relationship between 
Gadolinium and Nephrogenic Systemic Fibrosis[26-28], calls for the 
introduction of paramagnetic complexes alternative to the Gd-based 
ones that are currently used in the clinical practice. Manganese is an 
essential metal in living systems and it may represent a viable 
alternative to Gd as cells have set-up well established 
storing/excretion pathways for controlling its homeostasis. 
Furthermore, Mn-Apo can be proposed in the diagnosis of a variety 
of liver diseases involving an alteration in the hepatic iron storing 
capabilities and ferritin receptor expression (e.g. hepatocarcinoma, 
fibrosis, cirrhosis). The administration of MnII aqua ions well 
confined within the ferritin inner cavity appears an efficient method 
to conjugate low toxicity with high efficacy. The outer surface of 
Mn-Apo can be easily functionalized in order to endow it with 
targeting capabilities and design Mn-probes characterized by very 
high sensitivity. Apoferritin does not stimulate any immune reaction 
thus allowing for the design of probes that may stay in circulation 
for a time sufficiently long for specific targeting needs typical of 
Molecular Imaging diagnostic procedures.  
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Reduction/Dissolution of the inorganic -
MnOOH nanophase in the ferritin cavity 
to yield a high sensitivy, biologically 
compatible MRI agent  
An innovative approach to the design of MRI Contrast Agents has been pursued 
through the entrapment of MnII aqua ions inside the Apoferritin cavity. This task has 
been addressed by partial reduction/dissolution of the previously formed -MnOOH. 
The reductive treatment has allowed to generate an apoferritin-based nanocarrier 
containing up to 300-400 MnII aqua ions. This yielded to the remarkable relaxivity 







Preparation of Mn-reconstituted apoferritin: The iron-free horse spleen apoferritin (Sigma-Aldrich) was 
reconstituted in the presence of MnCl2 solution (Fluka, Mn Standard) at pH = 9.0, under air. To avoid the fast 
oxidation of the MnII ion, the apoferritin and MnII were added into a N2-saturated AMPSO (N-(1,1-Dimethyl-2-
hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid) (Fluka, ≥ 99.0 %) solution. The protein and the Mn(II) 
solution were added to give a 1×10–6 and 3×10–3 M concentration (3000 MnII/apoferritin), respectively. After 1 
week reaction time, the samples were concentrated using Vivaspin centrifugal concentrators (50000 MWCO), 
treated with NTA (2-(bis(carboxymethyl)amino)acetic acid) (Fluka, ≥ 99.0%) or TETA (1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) (Fluka, ≥ 97%) aminopolycarboxylates (in 1 to 1 metal to ligand 
ratio) to reduce MnIII as well as to eliminate MnOOH particles and the bound MnII ions from the outer surface of 
the protein shell. The reductive treatment was carried out at pH = 7.4 in HEPES buffer (Sigma-Aldrich) at different 
reaction time (0 – 7 h). To wash out the soluble species the samples were dialysed using cellulose membrane 
(Sigma-Aldrich, M.W. 12000). The dialysis was carried out at pH = 7.0 and the solution (2 l) was changed after 4 
hours and continued overnight. After the dialysis, samples were centrifuged (7000 rpm) to eliminate the aggregated 
and precipitated materials. At the end of this process the concentration of the protein (Bradford method, BSA 
standard) and the metal was measured. The metal concentration in a given volume was determined by adding the 
same volume of HCl 37% and left at 120 C overnight. By measuring the water proton relaxation rate of these 
solutions, it is possible to determine its concentration.  
TEM: High-resolution transmission electron microscopy analyses were performed on a JEOL JEM 3010-UHR, 
operating at 300 kV. Samples were dispersed on a lacey carbon Cu grid. 
Proton Nuclear Magnetic Relaxation Dispersion (NMRD) 1/T1 profiles: Data were measured at 25 °C over a 
continuum of magnetic field strengths from 0.00024 to 0.47 T (corresponding to 0.01-20 MHz proton Larmor 
Frequency) on a Stelar field-cycling relaxometer (Stelar, Mede, Italy), under complete computer control with an 
absolute uncertainty of 1%. Data points from 0.47 T (20 MHz) to 1.7 T (70 MHz) were collected on a Spinmaster 
spectrometer (Stelar, Mede, Italy) working at variable field. 
Chromatography: The high-performance liquid chromatography (HPLC) characterization of Mn-apo, prepared as 
described above, was carried out on an Amersham Akta Purifier chromatographic system equipped with an 
Amersham Superose 6 size-exclusion column (XK 16/30, G.E. Healthcare). The experimental workup was carried 
out in an isocratic condition at 1.0 ml/min, using an aqueous mobile phase containing Hepes 5 mM and NaCl 0.14 
M (pH = 7.4). 
EPR: X-band CW-EPR spectra were recorded on a Bruker (EMX) spectrometer equipped with a cylindrical cavity 
operating a 100 kHz field modulation. Spectra were recorded at RT in a 50 µl capillary tube using 10 mW of 
incident microwave power and a modulation amplitude of 3 G.  
 
